Dawson James analyst Jason Kolbert maintained a Hold rating on Soligenix (SNGX – Research Report) on February 2. The company’s shares closed last Tuesday at $0.62, close to its 52-week low of $0.58.
According to TipRanks.com, Kolbert is a 3-star analyst with an average return of 2.3% and a 39.2% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics.
The word on The Street in general, suggests a Hold analyst consensus rating for Soligenix.
See Insiders’ Hot Stocks on TipRanks >>
Based on Soligenix’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.59 million. In comparison, last year the company earned revenue of $507.2K and had a GAAP net loss of $1.79 million.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SNGX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the following segments: BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.
Read More on SNGX:
- Anavex Life Sciences (AVXL) Receives a Buy from Dawson James
- Dawson James Thinks Safe-T Group’s Stock is Going to Recover
- Dawson James Thinks Bluejay Diagnostics’ Stock is Going to Recover
- Dawson James Thinks Can-Fite BioPharma’s Stock is Going to Recover
- Dawson James Thinks 22nd Century’s Stock is Going to Recover
